re: Ann: Letter to Shareholders from the Boar... FOTH,
Fairly certain they did.
By the way, it is not unusual for a company not to mention a competitor or play it down.
Again, I heard all of the complaints about ATC by talking to biotech people well before (years) Avexa canned ATC. The only one that wasn't mentioned was the innaproriate size of the 800mg dose for combo therapies. The company must have known that one for a while, though.
Cheers,
Bob
Add to My Watchlist
What is My Watchlist?